SCA
CHRS icon

Spearhead Capital Advisors’s Coherus Oncology CHRS Stock Holding History

Spearhead Capital Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25,718
Closed -$410K – 202
2021
Q4 		$410K Buy
25,718
+298
+1% +$5.21K 0.05% 116
2021
Q3 		$408K Sell
25,420
-188
-0.7% -$2.76K 0.05% 123
2021
Q2 		$354K Buy
25,608
+4,179
+20% +$59.2K 0.05% 162
2021
Q1 		$313K Buy
+21,429
New +$364K 0.05% 159

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Spearhead Capital Advisors's CHRS Position: Q1 2022 in Review

Spearhead Capital Advisors sold out of Coherus Oncology (CHRS) in Q1 2022, closing a stake of 25,718 shares — an estimated $410K sold.

Spearhead Capital Advisors first reported a position in CHRS in Q1 2021 and held it in 4 quarters. The position peaked at $410K in Q4 2021. 183 funds tracked by Wall St. Rank hold CHRS as of Q1 2022.

  • Spearhead Capital Advisors reported no remaining Coherus Oncology position as of Q1 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 25,718 Coherus Oncology shares in Q1 2022, an estimated $410K.
  • Spearhead Capital Advisors first reported a position in Coherus Oncology in Q1 2021 and held it in 4 quarters.
  • Spearhead Capital Advisors's Coherus Oncology position peaked at $410K in Q4 2021.
  • 183 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2022.

Based on Spearhead Capital Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.